

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

- 1-32. (Cancelled).
33. (Previously presented) An expression vector comprising:
a transcriptional start site;
a promoter operably linked to the transcriptional start site; and
a ζ -globin enhancer operably linked to the promoter, the enhancer comprising a nucleotide sequence of SEQ. ID NO:1 or its complement;
wherein the expression vector is a retroviral vector.
34. (Previously presented) The expression vector of claim 33, wherein the promoter drives transcription of an mRNA.
35. (Previously presented) The expression vector of claim 34, wherein the mRNA encodes a growth hormone.
36. (Previously presented) The expression vector of claim 33, wherein the promoter is a ζ -promoter.
37. (Previously presented) The expression vector of claim 33, wherein the nucleotide sequence is SEQ ID NO:2 or its complement.
38. (Previously presented) The expression vector of claim 37, wherein the promoter is a ζ -promoter.

39. (Previously presented) The expression vector of claim 33, wherein the nucleotide sequence is SEQ ID NO:3 or its complement.

40. (Previously presented) The expression vector of claim 39, wherein the promoter is a ζ -promoter.

41-44. (Cancelled).

45. (Previously presented) The expression vector of claim 36, wherein the promoter drives transcription of an mRNA.

46. (Previously presented) The expression vector of claim 45, wherein the mRNA encodes a growth hormone.

47-50. (Cancelled).

51. (Previously presented) A method of expressing a transcript in an isolated cell, the method comprising introducing a retroviral expression vector into the cell, the expression vector including:

- a transcriptional start site;
- a nucleic acid sequence operably linked to the transcriptional start site, the nucleic acid sequence encoding the transcript;
- a promoter operably linked to the transcriptional start site; and
- a ζ -globin enhancer operably linked to the promoter, the enhancer having a nucleotide sequence of SEQ. ID NO:1 or its complement.

52. (Previously presented) The method of claim 51, wherein the promoter drives transcription of an mRNA.

53. (Previously presented) The method of claim 51, wherein the promoter is a ζ -promoter.

54. (Previously presented) The method of claim 51, wherein the nucleotide sequence is SEQ ID NO:2 or its complement.

55. (Previously presented) The method of claim 54, wherein the promoter is a ζ -promoter.

56. (Previously presented) The method of claim 51, wherein the nucleotide sequence is SEQ ID NO:3 or its complement.

57. (Previously presented) The method of claim 56, wherein the promoter is a ζ -promoter.

58-63. (Cancelled).